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Abstract
Background: Increased in susceptibility to thrombotic disease may be associated with lower lung function. If causal, this
association may suggest an area for development of new interventions for lung disease. The aim of this study was to
investigate the association between blood coagulation activation as measured by plasma d-dimers and lung function.
Methodology/Principal Findings: We conducted a cross-sectional study on 2463 randomly selected adults in 1991 and
followed up 1252 of these individuals in 2000. Plasma D-dimer levels, a marker of activity of blood coagulation pathways,
were analysed in the baseline 1991 samples. There was an inverse cross-sectional association between plasma D-dimer and
Forced Expiratory Volume in one second, with a decrease of 71 ml per mg FEU/ml increment in plasma D-dimer (95%
confidence intervals CI: 2135 to 26), and a decrease in Forced Vital Capacity (97 ml per mg FEU/ml increase in D-dimer,
95%CI: 2170 to 224). These associations were attenuated after adjustment for serum highly sensitive CRP. No association
was observed between plasma D-dimer and the decline in lung function between 1991 and 2000.
Conclusions/Significance: The cross-sectional findings are consistent with the hypothesis that activation of blood
coagulation pathways is associated with decreased lung function, and that systemic inflammation may contribute to this
relation. However, the lack of an association with decline in lung function suggests that clotting pathways that involve d-
dimers may not be a promising therapeutic target for new interventions for respiratory disease.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a common
disease characterised by reduced lung function and obstructive
airflow limitation [1]. Although some exposures, notably smoking
[2], pollution [3] and diet [4] are recognised aetiological factors for
COPD, residual variation exists between individuals that remains
to be explained. Identification of reversible factors demonstrated
to modify lung function is a priority, as this may lead to new
interventions to prevent chronic lung disease.
Systemic coagulation pathways have the potential to influence
pulmonary function as the lungs are a highly vascular organ, and
in addition to gas exchange they also have the role of filtering the
venous blood, thus preventing thrombotic micro-emboli from
entering the arterial circulation. The importance of the lung in
filtering the blood of microscopic particles is highlighted in patients
with untreated arterio-venous malformations, of whom approxi-
mately 36% experience cerebral events, probably as a conse-
quence of micro-emboli in the cerebral circulation [5]. The
hypothesis that factors that increase thromboembolic risk may also
contribute to structural damage to the lungs is supported by the
observation that homozygotes for factor V Leiden gene, who have
a genetic predisposition resulting in a hypercoagulable state, had
an annual loss of forced expiratory volume in one second (FEV1)o f
39 ml/year, as compared to 21 ml/year in a study of those who
were not homozygotes [6]. Fibrinogen, another constituent of the
clotting cascade, is positively associated with an increase in
vascular diseases [7], inversely related to lung function cross-
sectionally [8], and positively associated with the increased loss of
lung function [9] and development of an obstructive lung
physiological phenotype [10]. Recent work on the molecular
processes that underpin the pathophysiology of COPD has also
implicated inappropriate activation of the coagulation cascade and
in particular thrombin and plasmin as potential factors that may
promote pulmonary inflammation, airway remodelling and
eventually the development of emphysema via protease activated
receptors [11].
These data thus suggest that higher systemic clotting pathway
activity may be a modifiable risk factor for lower lung function.
Activation of clotting pathways can be measured by D-dimer, a
fibrin degradation product that is a consequence of systemic
thrombotic activity [12]. The aim of this study is to test the
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function using data from a randomly selected population of 2633
individuals based in Nottingham. We have also investigated how
these associations may be modified by controlling for levels of C-
reactive protein, a marker of systemic inflammation. The results
suggest a cross-sectional association between plasma d-dimers and
lung function that is attenuated by adjustment for systemic
inflammation, but no association between plasma d-dimers and
change in lung function over nine years.
Materials and Methods
Ethics Statement
The study was approved by the Nottingham City Hospital
Ethics Committee.
Study population
The participants are drawn from a previously reported
community-based population of 2633 adults aged 18–70 living
in Nottingham first studied in 1991 [13]. In brief, a sample of 7106
adults aged 18 or over were identified from a population of
approximately 87 000 living in a Local Authority Area of
Nottingham, UK by systematic sampling from a random starting
point in the electoral register. All subjects aged 18–70 on 1
st
January 1991 were invited in writing to attend a local surgery or
Health Centre where they were interviewed by a doctor who
explained the study protocol. In 2000, all surviving individuals
were invited to participate in a follow-up cohort study [4]. Written
consent was obtained from all study participants.
Data collection
In 1991 and 2000 participants were asked to abstain from
inhaled bronchodilators for four hours and from oral bronchodi-
lators for eight hours before their study visit. Subjects completed a
computer-administered lifestyle questionnaire. FEV1 and FVC
were then measured using a dry bellows spirometer (Vitalograph,
Buckingham, UK), taking the best of three technically satisfactory
manoeuvres with the subject seated. After venesection, plasma
samples were separated by centrifugation, typically within 15
minutes, and stored at 280u centigrade. These samples were
subsequently defrosted and D-dimer measured using an immuno-
turbidiometric test (Olympus OSR60135) on an Olympus
AU5400 analyser (Miami, FL) in 2008.
Statistical analysis
Smoking status was defined in three categories; current smoker
(those who had smoked within one month of the study in 1991 or
2000), ex-smoker (those who had not smoked for at least one
month before the appointment in 1991 or 2000) and never
smokers. Smoking data from 1991 were used to validate never-
smoking status in 2000. The number of pack-years smoking
exposure was estimated for subjects from their reported age at
starting smoking, and the usual amount smoked during this
period.
We analysed the cross-sectional association between plasma D-
dimer and FEV1 using a similar analytical approach to that used
previously in this dataset [13]. We used multiple linear regression
with adjustment for a priori confounding factors of age, age
squared, sex, height, body mass index (BMI), smoking status and
total of cigarette pack years smoked. Potential confounding factors
including vitamin C and magnesium intake that have been
previously associated with lung function were investigated by
adding them to the a priori model and if the size of effect changed
by 10% or more they were considered to be a potential
confounding factor and retained in the final model. We examined
the shape of the relation between D-dimer and FEV1 by plotting
D-dimer in quintiles, and linearity was subsequently tested using
the likelihood ratio test. As the relation was linear, results were
presented as change in FEV1 per unit change in plasma D-dimer
and also graphically using quintiles to provide a more accessible
representation of the size of the associations observed. Repeating
the analysis using D-dimer as a logged variable made no
appreciable difference to the fit of the model. As serum highly
sensitive CRP is positively correlated with D-dimer [14] and also
inversely associated with lung function [15], the effect of highly
sensitive CRP on the association between D-dimer and lung
function was modelled independently as it may be on the causal
pathway linking these variables. Interactions for gender, smoking
status and BMI on the relation between plasma D-dimer and
FEV1 and FVC were investigated and considered significant at the
value of p,0.05. The analyses were carried out using STATA
version ten (Stata Corporation, College Station, Texas).
The longitudinal analysis used both the 1991 and 2000 datasets
and the modelling strategy has been previously described [4].
Briefly, predicted FEV1 values were modelled in our dataset for
each gender in non-smoking, non-asthmatic, non-wheezing
individuals with terms for age, height, age-squared and age-height
interactions. Individual FEV1 values were expressed as the residual
difference from the predicted value, and these values were used to
create a single value of change in residual by subtracting the 1991
residual from the 2000 residual. The association between plasma
D-dimer and change in residual value of FEV1 was modelled
independently using multiple linear regression to adjust for
smoking status, smoking pack years and body mass index.
With over 2400 individuals providing cross-sectional data, and
using a standard deviation for FEV1 of 900 ml, we calculate that
we would have over 90% power to detect a difference of 40 ml in
FEV1 between quintiles of D-dimer. In the longitudinal analysis,
with 1250 samples of plasma, and using data from this dataset of a
SD of 291 ml for decline in FEV1 over nine years, the study would
have over 90% power to detect a linear trend in decline in FEV1
with increasing quintiles of D-dimer equivalent to 2 ml/year per
increasing quintile.
Results
2633 individuals provided complete data in 1991 (Table 1) and
of these 1346 (51%) were followed up and provided further data in
2000 (Table 2). 2463 (94%) of those who participated in 1991
provided a sample for analysis of plasma D-dimer and these were
generally representative of the total study population.
The median value for plasma D-dimer was 0.14 mg fibrinogen
equivalent units (FEU)/ml (interquartile range 0.08 to 0.23). In the
1991 dataset serum highly sensitive CRP was positively associated
with plasma D-dimer (regression coefficient, +0.012 FEU/ml per
increment in highly sensitive CRP in mg/l, p,0.001). Those who
attended in both 1991 and 2000 had a median plasma d-dimer of
14 (FEU)/ml, while those who attended in 1991 only also has a
median plasma d-dimer of 14 (FEU)/ml (p=0.44 for difference,
Mann-Whitney test).
Cross-sectional analysis of d-dimers and lung function
There was an inverse association between plasma D-dimer and
FEV1 (Figure 1), with a decrease of 71 ml per mg FEU/ml
increment in plasma D-dimer (95% confidence intervals CI: 2135
to 26) after adjusting for potential confounding factors (Table 3).
Similar associations were observed between plasma D-dimer and
FVC, with a decrease of 97 ml per unit increase in D-dimer
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these associations by smoking status, gender or BMI.
Addition of serum highly sensitive CRP to the final model
reduced the strength of these associations for both FEV1 (250 ml
per mg FEU/ml increase in D-dimer; 95%CI: 2115 to +16) and
FVC (269 per mg FEU/ml in D-dimer; 95%CI: 2143 to +6). No
association was observed between plasma D-dimer and the FEV1/
FVC ratio in the cross-sectional population.
Longitudinal analysis of d-dimers and decline in lung
function
There was no association between baseline plasma D-dimer and
decline in FEV1 as measured by the change in residual values over
nine years, with a change in residual FEV1 of +22.7 ml (95%CI:
227.7 to +73.1) after adjustment for BMI, smoking status and
pack years smoked. Similarly, no effect modification of these
associations between lung function and plasma D-dimer by
smoking status, gender or BMI were observed.
Discussion
In this study, we report for the first time that higher levels of
plasma D-dimer are associated with lower FEV1 and FVC cross-
sectionally in a randomly selected population and that this
association is reduced after adjustment for highly sensitive CRP
as a biomarker for systemic inflammation. However, plasma D-
dimer levels were not associated with an accelerated decline in
lung function over nine years.
The population studied was a random sample from the electoral
register of a Local Authority Area in Nottingham, and is thus likely
to be a representative sample of the general population.
Physiological measurements of lung function and blood samples
were collected in a standardised manner. As we used archived
serum from 1991 to assess the level of D-dimer that was frozen at
280 degrees Celsius and analysed by one clinical chemist using
the same assays and equipment, we are confident that we have
minimised bias due to the storage and analysis of the samples.
Table 1. Baseline characteristics of study population.
Total study population
Provided blood for baseline
D-dimer analysis
Did not provide blood for
baseline D-dimer analysis
Number of participants 2633 2463 170
Males N (%) 1312 (50%) 1223 (50%) 89 (52%)
Age mean in yrs (sd) 44.4 (13.6) 44.6 (13.5) 41.3 (14.9)
Mean height m (sd) 1.68 (0.1) 1.68 (0.1) 1.70 (0.1)
Mean body mass index kg/m
2 (sd) 25.5 (4.0) N=2614 25.5 (4.0) N=2445 25.6 (4.5) N=169
Smoking status N (%) Never Ex Curren 1306 (50) 1209 (49) 97 (57)
730 (28) 694 (28) 36 (21)
597 (23) 560 (23) 37 (22)
Baseline FEV1 - L (sd) 3.19 (0.9) 3.18 (0.9) 3.3 (0.9)
Baseline predicted FEV1 % (sd) 99.4 (0.9) 99.6 (17.6) 98.9 (15.9)
Baseline FVC - L (sd) 3.94 (1.1) 3.9 (1.1) 4.0 (1.1)
Baseline Predicted FVC % (sd) 102.9 (16.3) 103.1 (16.3) 100.9 (15.7)
FEV1 in 2000 - L (sd) 2.84 (0.85) N=1343 2.84 (0.85) N=1275 2.87 (0.78) N=68
FVC in 2000 – L (sd) 3.67 (1.01) N=1342 3.67 (1.01) N=1274 3.67 (0.94) N=68
Median D-dimer (mg FEU/ml) - 0.14 (0.08–0.23) -
Median highly sensitive CRP (mg/l) IQR 1.14 (0.55 to 2.42) N=2442 1.14 (0.55 to 2.42) N=2396 1.28 (0.51 to 2.17) N=46
FEV1 = Forced Expiratory Volume in one second.
FVC = Forced Vital Capacity.
IQR = interquartile range.
doi:10.1371/journal.pone.0015014.t001
Table 2. Rates of follow up and change in lung function of study population by categories of baseline d-dimers in quintiles.
Quintiles of
d-dimers in 1991 Number
Provided data
in 2000 (%)
Change in FEV1 over
study period(sd)
Change in FVC over
study period (sd)
1 560 288 (51) 2350 (291) 2282 (376)
2 436 218 (50) 2319 (281) 2233 (368)
3 517 264 (51) 2328 (283) 2304 (410)
4 475 266 (56) 2362 (324) 2283 (417)
5 475 242 (51) 2345 (272) 2260 (383)
FEV1 = Forced expiratory volume in one second.
FVC = Forced Vital Capacity.
sd = standard deviation.
doi:10.1371/journal.pone.0015014.t002
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d-dimers are the same in long-term frozen samples like ours
compared to fresh samples, the standardised storage and analysis
of our samples gives us confidence in the integrity of the
comparative analyses within the group as a whole. Serum samples
stored for similar periods of time have shown significant
associations of D-dimer, and CRP, with risk of cardiovascular
disease, and with risk factors such as cigarette-smoking [14,16].
While participation in the follow-up study was potentially biased
by survival, nonmigration and motivation to participate, our data
suggest that the participants in 2000 were broadly similar to the
original population in terms of diet, smoking history, initial lung
function and history of respiratory disease [4]. Our response rate
of 51% of the original study population raises concerns regarding
response bias, particularly as elevated plasma D-dimer is a
prognostic marker of increased cardiovascular disease [16] and
potentially for mortality, although there was no difference in
baseline D-dimer in those who attended for the second visit nine
years after baseline compared to those who did not. Thus, it is
important to emphasize that our data do not exclude an
association between increased activity of systemic coagulation
pathways and increased decline in lung function, and that larger
population-based studies of change in lung function with shorter
intervals between data collection will be required to clarify this
important question.
Our original hypothesis was that higher levels of activation of
blood coagulation would be associated with lower lung function.
Our data were consistent with this hypothesis in the cross-sectional
analysis prior to adjustment for systemic inflammation, although
the attenuation of this association after adjustment for systemic
inflammation suggests that this requires consideration in any
further studies of clotting activity and lung function. Our
longitudinal analysis demonstrated no association between plasma
D-dimer and decline in lung function. We speculate that one
potential explanation to reconcile these differing results is that
factors in early life that modify lung development also influence
activity of the coagulation pathways in later years. This is
consistent with the observation that individuals with lower lung
function have a higher risk of myocardial infarction [17] – for
which elevated D-dimer levels are an independent risk factor
[14,16].
Although the hypothesis that acute changes in blood coagu-
ability in response to particulate pollution may account for some of
the variation in cardio-respiratory disease rates is an established
one [18], we consider that the concept that chronic differentials in
systemic coagulative activity may impact on lung function is an
emerging concept supported by Mendelian randomisation tech-
niques. Homozygotes for factor V Leiden gene, who have a
genetic predisposition resulting in a chronic hypercoagulable state,
have an annual loss of forced expiratory volume in one second
Figure 1. The cross-sectional association of D-dimer (mg FEU/ml) with Forced Expiratory Volume in one second compared to the
lowest quintile (reference group). FEV1 = Forced Expiratory Volume in one second adjusted for sex, age, age squared, height, BMI, smoking
status (categorical), smoking pack years
doi:10.1371/journal.pone.0015014.g001
Table 3. The cross-sectional association of D-dimer (mg FEU/
ml) with Forced Expiratory Volume in one second and Forced
Vital Capacity.
Number of
individuals FEV1 (ml) FVC (ml)
D-dimer* 2445 271 (2135 to 26) 297 (2170 to 224)
D-dimer* + highly
sensitive CRP
2379 250 (2115 to +16) 269 (2143 to +6)
*Model adjusted for sex, age, age squared, height, BMI, smoking status
(categorical) and smoking pack years.
95% confidence intervals in brackets.
FEU = Fibrinogen equivalent units.
FEV1 = Forced Expiratory Volume in one second.
FVC = Forced Vital Capacity.
BMI = body mass index.
CRP = C-Reactive protein.
doi:10.1371/journal.pone.0015014.t003
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hypothesis is supported by reports that fibrinogen, another
constituent of the clotting cascade, is inversely related to lung
function cross-sectionally [8,10], and also positively associated
with increased loss of lung function [9] and the development of
obstructive lung physiology [10]. The hypothesis that higher levels
of chronic activation of the coagulation pathways may impact on
lung pathophysiology is consistent with the observation of the
impact of air pollution with regard to the pulmonary vasculature
in a study in animals from areas of varying air pollution,
demonstrating high levels of microthrombi in the lungs on autopsy
in the dogs from Mexico City compared to dogs from less polluted
areas where few no micro-thrombi observed [19]. As air pollution
is also a risk factor for lower lung function in children [20] it may
impact on lung function by a vascular mechanism in addition to its
direct toxic effects on the lungs.
Serum highly sensitive CRP has been demonstrated to be
inversely associated with lung function in a variety of datasets
including ours [15,21,22], and as it is indicative of a systemic
inflammatory response, we consider that it may be on a causal
pathway that links higher coagulation activity with lower lung
function. This is consistent with the observation that increased
systemic inflammation is associated with elevated blood D-dimer
levels both in our dataset and elsewhere [14]. An alternative
explanation is that higher serum highly sensitive CRP is a
biomarker for lower lung function and that the apparent
associations between coagulation pathway activity and lung
function that we have observed are in part a consequence of
confounding.
Thus, our data are broadly consistent with a range of evidence
that increased blood coagulation activity is inversely cross-
sectionally associated with pulmonary function, although also
demonstrate that future cross-sectional studies in this area should
consider systemic inflammation, which may be either a confound-
ing factor or potentially involved in a causal pathway for these
associations. However, the lack of an association with decline in
lung function suggests that clotting pathways that involve d-dimers
may not be a promising therapeutic target for new interventions
for respiratory disease.
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